Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Progression-free survival

In recent years, with the emergence and clinical application of anti-angiogenesis therapy,
 the therapeutic effect of patients has been significantly improved while ensuring that the
 adverse reactions of patients do not increase. Anti-angiogenic therapy can improve the
 hypoxia state of tumor tissue, normalize blood vessels, relieve immune suppression in tumor
 microenvironment, increase the degree of infiltration of immune cells, and fully activate
 immune cells to achieve the effect of tumor immunity. Previous studies have shown that
 penpulimab injection combined with anlotinib in the treatment of NSCLC can induce the
 normalization of tumor blood vessels and reshape the tumor immunosuppressive
 microenvironment, and the combination of the two can have synergistic effects.
 
 This study intends to treat patients with advanced non-small cell lung cancer (NSCLC)
 confirmed by pathology with the combination of anlotinib and penpulimab injection, and
 observe the efficacy and safety of anlotinib and penpulimab injection in the first and second
 lines of NSCLC. This study is expected to provide a reference for the treatment strategy of
 advanced non-small cell lung cancer patients, and has important clinical value for the
 treatment of advanced lung cancer.